Search results for "ThioTEPA"

showing 10 items of 20 documents

Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation i…

2017

Eighty-one patients with high-risk hematological malignancies received unmanipulated haploidentical stem cell transplants (haploSCT) using the same protocol at four Spanish institutions. The conditioning regimen was thiotepa, busulfan and fludarabine; following bone marrow or peripheral blood infusion. GvHD prophylaxis with high-dose cyclophosphamide on days +3 and +4, and IV tacrolimus from day +5 was administered. 62% were in complete remission, 17% had received previous allogeneic SCT and 44% had a high-very high refined disease risk index. One patient had primary graft failure and three more died before +21. The median days to neutrophil and platelet recoveries were +18 and +23, respect…

AdultMalemedicine.medical_specialtyTransplantation ConditioningCyclophosphamideAdolescentGraft vs Host DiseaseThioTEPAGastroenterologyTacrolimus03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineHumansCyclophosphamideAgedRetrospective StudiesTransplantationbusiness.industryHematologyMiddle Agedmedicine.diseaseTacrolimusFludarabineSurgeryTransplantationsurgical procedures operativemedicine.anatomical_structureGraft-versus-host disease030220 oncology & carcinogenesisHematologic NeoplasmsTransplantation HaploidenticalFemaleBone marrowbusinessBusulfanImmunosuppressive Agents030215 immunologymedicine.drugBone marrow transplantation
researchProduct

Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Trans…

2020

In this prospective randomized study, we compared the outcomes of single-unit umbilical cord blood transplantation (UCBT) and unmanipulated haploidentical stem cell transplantation (haplo-SCT) with post-transplantation cyclophosphamide (PTCy) in adults with hematologic malignancies. All patients received a myeloablative conditioning (MAC) regimen consisting of thiotepa, busulfan, and fludarabine, with antithymocyte globulin (ATG) added for UCBT recipients. Nineteen patients were randomized to UCBT and the other 26 to haplo-HSCT. Four patients (15%) allocated to the haplo-HSCT arm lacked a suitable donor and were crossed over to the UCBT arm. Finally, 23 underwent UCBT and 22 underwent haplo…

Adultmedicine.medical_specialtyendocrine systemHematologic malignancyTransplantation ConditioningHaploidentical transplantationGraft vs Host DiseaseContext (language use)ThioTEPAGastroenterologyMAC Regimen03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCumulative incidenceProspective StudiesTransplantationAllogeneic stem cell transplantation clinical trial Alternative donor transplantation Haploidentical transplantation Hematologic malignancy Umbilical cord blood transplantationUmbilical cord blood transplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyAlternative donor transplantationFludarabineTransplantationRegimenAllogeneic stem cell transplantation clinical trialsurgical procedures operative030220 oncology & carcinogenesisHematologic NeoplasmsCord Blood Stem Cell TransplantationNeoplasm Recurrence LocalbusinessBusulfan030215 immunologymedicine.drug
researchProduct

Mitomycin C from birth to adulthood.

2016

Mitomycin C (MMC) intravesical therapy for “superficial” papillary bladder tumors was firstly introduced in the early seventies with promising results. In the following years, several pharmacokinetic studies investigated its mechanism of action to optimize the intravesical administration. Numerous studies confirmed thereafter both the ablative and the prophylactic efficacy and the low toxicity of MMC when intravesically given. In 1984, a complete response rate of 42% in 60 patients not responsive to thiotepa was reported with intravesical MMC at the dose of 40 mg diluted in 40 ml for 8 weeks. In the following decades, many large randomized studies showed the benefit of intravesical prophyla…

Adultmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMitomycinAntibiotics030232 urology & nephrologyUrologyThioTEPASettore MED/24 - Urologia03 medical and health sciencesYoung Adult0302 clinical medicinePharmacokineticsMedicineHumansYoung adultChildComplete responseAntibiotics Antineoplasticbusiness.industryMedicine (all)digestive oral and skin physiologyMitomycin CGeneral MedicineRegimenUrinary Bladder Neoplasms030220 oncology & carcinogenesisUrinary Bladder NeoplasmbusinessAdjuvantHumanmedicine.drugUrologia
researchProduct

Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.

2020

In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results. The outcomes of SIR-TAC in a more intense RIC regimen as Thiotepa-fludarabine-busulfan (TBF) have been hardly investigated. This retrospective study included all consecutive patients receiving an allogeneic hematopoietic stem cell transplantation for myeloid malignancies (January 2009-2017) conditioned with either TBF or BF and receiving SIR-TAC. Patients receiving TBF presented higher non-relapse mortality (31.6 vs 12.3%,p = .01), along with shorter overall survival …

Cancer Researchmedicine.medical_specialtyTransplantation ConditioningUrologyGraft vs Host Diseasechemical and pharmacologic phenomenaThioTEPAReduce intensity conditioningsirolimus and tacrolimusgraft vs host disease prophylaxisTacrolimus03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesreduce intensity conditioningmedicineHumansHost diseaseBusulfanRetrospective StudiesSirolimusallogeneic hematopoietic cell transplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyTacrolimusFludarabinesurgical procedures operativeOncology030220 oncology & carcinogenesisSirolimusFeasibility StudiesConditioningThiotepa-fludarabine-busulfanbusinessThiotepaVidarabineBusulfan030215 immunologymedicine.drug
researchProduct

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the firs…

2016

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.METHODS: For the international randomised phase 2 International Extranodal Lymphoma Study Group-32 …

MaleComparative Effectiveness ResearchTransplantation ConditioningGastrointestinal DiseasesDenmarkMedizinKaplan-Meier EstimateDexamethasoneCentral Nervous System NeoplasmsDeath Sudden0302 clinical medicineIntraocular LymphomaGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicineStandard treatmentOptic Nerve NeoplasmsPoisoningRemission InductionCytarabineHematopoietic Stem Cell TransplantationAnemiaHematologyInduction ChemotherapyAcute Kidney InjuryMiddle AgedCombined Modality TherapyMagnetic Resonance Imaging3. Good healthStrokeTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesischemoimmunotherapyRituximabFemaleNeurotoxicity SyndromesChemical and Drug Induced Liver InjuryRituximabSwitzerlandmedicine.drugMucositismedicine.medical_specialtyLymphoma B-CellNeutropeniaThioTEPAInfectionsTransplantation AutologousDisease-Free Survival03 medical and health sciencesprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal Articleprimary CNS lymphoma chemoimmunotherapyHumansbusiness.industryThrombosismedicine.diseaseThrombocytopeniaUnited KingdomSurgeryTransplantationRegimenMethotrexateHeart InjuriesHyperglycemiaRadiotherapy Adjuvantbusiness030217 neurology & neurosurgeryFebrile neutropeniaThiotepaFollow-Up StudiesThe Lancet. Haematology
researchProduct

Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease

2016

We report the outcome of 30 consecutive patients with Hodgkin disease (HD) who underwent single-unit UCBT. Most (90%) patients had failed previous autologous hematopoietic stem cell transplantation. The conditioning regimens were based on combinations of thiotepa, busulfan, cyclophosphamide or fludarabine, and antithymocyte globulin. The cumulative incidence (CI) of myeloid engraftment was 90% [95% confidence interval (C.I.), 74-98%] with a median of 18 d (range, 10-48). CI of acute graft-versus-host disease (GvHD) grades II-IV was 30% (95% C.I., 17-44%), while the incidence of chronic GVHD was 42% (95% C.I., 23-77%). The non-relapse mortality (NRM) at 100 d and 4 yr was 30% (95% C.I., 13-4…

MaleHerpesvirus 4 HumanTransplantation Conditioningmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceHodgkin's lymphomaIncidence (epidemiology)Graft Survivalumbilical cord blood transplantationHematologyGeneral MedicineMiddle AgedHodgkin DiseaseFludarabine030220 oncology & carcinogenesisAcute DiseaseFemaleCord Blood Stem Cell TransplantationVidarabinemedicine.drugAdultmedicine.medical_specialtyCyclophosphamideThioTEPA03 medical and health sciencesInternal medicinemedicineHumansInfectious MononucleosisBusulfanCyclophosphamideAntilymphocyte Serumbusiness.industryMyeloablative AgonistsHodgkin's lymphomamedicine.diseaseSurvival AnalysisSurgeryEBV post-transplant lymphoproliferative diseaseChronic DiseaseEBV post-transplant lymphoproliferative disease; Hodgkin's disease; Hodgkin's lymphoma; umbilical cord blood transplantationHodgkin's diseasebusinessSettore MED/15 - Malattie del SangueThiotepaBusulfan030215 immunologyEuropean Journal of Haematology
researchProduct

A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based …

2017

There is a paucity of data evaluating acute kidney injury (AKI) incidence and its relationship with the tacrolimus-sirolimus (Tac-Sir) concentrations in the setting of reduced-intensity conditioning (RIC) after allogeneic stem cell transplantation (allo-HSCT). This multicenter retrospective study evaluated risk factors of AKI defined by 2 classification systems, Kidney Disease Improving Global Outcome (KDIGO) score and "Grade 0-3 staging," in 186 consecutive RIC allo-HSCT recipients with Tac-Sir as graft-versus-host disease prophylaxis. Conditioning regimens consisted of fludarabine and busulfan (n = 53); melphalan (n = 83); or a combination of thiotepa, fludarabine, and busulfan (n = 50). …

MelphalanAdultMalemedicine.medical_specialtyTransplantation ConditioningUrologyReduced intensity conditioningGraft vs Host DiseaseThioTEPAurologic and male genital diseasesTacrolimus03 medical and health sciencesYoung Adult0302 clinical medicineParametric modeling of time-to-event dataRisk Factorshemic and lymphatic diseasesTime-to-event analysisMedicineHumansCumulative incidenceAgedRetrospective StudiesSirolimusTransplantationbusiness.industryAcute kidney injuryHematopoietic Stem Cell TransplantationHematologyAcute Kidney InjuryMiddle Agedmedicine.diseaseFludarabineSurgeryAcute kidney injuryAllogeneic stem cell transplantationTransplantationsurgical procedures operative030220 oncology & carcinogenesisFemalebusinessBusulfan030215 immunologymedicine.drugKidney disease
researchProduct

Permeability of the bladder mucosa to thiotepa, adriamycin, and daunomycin in men and rabbits.

1976

The permeability of the bladder mucosa to thiotepa and to the anthraquinonic antibiotics, adriamycin and daunomycin, was investigated both in humans and in experimental animals. Instillations in rabbits were performed either in intact males or in animals with ligated ureters. Absorption of thiotepa was significantly higher than that of the antibiotics both in men and in rabbits. Furthermore, a qualitative difference was observed in rabbits in relation to time and with regard to fixation to vesical tissues. In man, absorption was highest after transurethral surgery. It was also increased in cases with extensive anaplastic tumours or in the presence of acute inflammatory reactions.

NephrologyMalemedicine.medical_specialtyCancer chemotherapymedicine.drug_classUrologyAntibioticsUrinary BladderUrologyThioTEPAPharmacologyPermeabilityTransurethral surgeryInternal medicinemedicineAnimalsHumansQualitative differenceMucous MembraneChemistryBladder MucosaDaunorubicinDoxorubicinRabbitsThiotepamedicine.drugUrological research
researchProduct

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in…

2017

Background The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested. Here, we report the results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to wh…

OncologyAdultMalemedicine.medical_specialtyautologous stem cell transplantationAdolescentLymphomaMedizinprimary CNS lymphoma whole brain radiotherapy autologous stem cell transplantationPhases of clinical researchThioTEPATransplantation AutologousDisease-Free SurvivalCentral Nervous System Neoplasms03 medical and health sciencesYoung Adult0302 clinical medicineAutologous stem-cell transplantationprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal ArticleMedicineHumansAgedManchester Cancer Research CentreDose-Response Relationship Drugbusiness.industryResearchInstitutes_Networks_Beacons/mcrcInduction chemotherapyBrainHematologyMiddle AgedCombined Modality Therapy3. Good healthSurgeryTransplantationRegimenMethotrexate030220 oncology & carcinogenesiswhole brain radiotherapyRituximabFemalebusiness030215 immunologymedicine.drugStem Cell Transplantation
researchProduct

Cooperative studies of chemoprophylaxis after transurethral resection of bladder tumors

1983

Large cooperative trials are more likely than series studied by small groups to bring about significant progress in the field of intravesical adjuvant chemotherapy of superficial bladder tumor. Multicenter randomized trials involving large numbers of patients have been conducted in Europe by the EORTC Urological Group. The Group's main objectives were to compare the efficacy of thio-TEPA, VM-26, epodyl, Adriamycin, and cisplatin, against no treatment, and to study the prophylactic effect of oral pyridoxine and evaluate the main prognostic factors. The results obtained so far are reported. Preliminary information is also given about the Blinst study, a multicenter open investigation of local…

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsToxicologylaw.inventionRandomized controlled triallawInternal medicinemedicineCarcinomaHumansCombined Modality TherapyPharmacology (medical)DoxorubicinTeniposidePharmacologyCisplatinClinical Trials as TopicChemotherapyMulti-Institutional Systemsbusiness.industryPyridoxinePrognosismedicine.diseaseCombined Modality TherapyCarcinoma PapillaryClinical trialUrinary Bladder NeoplasmsOncologyDoxorubicinChemoprophylaxisCisplatinNeoplasm Recurrence LocalbusinessThiotepamedicine.drugCancer Chemotherapy and Pharmacology
researchProduct